Brind.
  1. Splash plans to seek U.S. regulatory approval and FDA approval for veterinary use.

SPLASH expanded its exclusive global license for CannEpil and is seeking a strategic joint venture for development.

1 report, 1 independent Updated Jul 31
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

SPLASH expanded its exclusive global license for CannEpil and is seeking a strategic joint venture for development.

Who's involved

What this event is mainly about
SPLASH

Keep exploring

Part of

Splash plans to seek U.S. regulatory approval and FDA approval for veterinary use. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped